@article{CJCR2028,
author = {Luxian Cao and Liangding Hu and Hu Chen and Chunjiang Deng and Xuetao Pei and Min Jiang and Bo Wang and Anwen Yan and Maoquan Qin},
title = {ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN THE TREATMENT OF LEUKEMIA},
journal = {Chinese Journal of Cancer Research},
volume = {9},
number = {2},
year = {2013},
keywords = {},
abstract = {We reported 14 leukemia patients transplanted with aliogeneic peripheral blood stem cells (AIIo-PBSCT) of HLA identical sibling, AML 5, ALL 4, CML 5. There were 12 patients in their early stage of leukemia, 2 in late stage. They were 32 (25-42) years old, 10 male and 4 female. After conditioned with CTX and frBl, G/GMCSF mobilized donor's peripheral blood mononuclear cells (MNC) 4.80 (2.46-8.43) x 108/kg and CD34+ cells 3.96 (1.01-10.08) x l06/kg were infused respectively. CSA and MTX used as GVHD prophylaxis. After Alio-PBSCT, WBC rose to 1.0 x 109/L on day + 17 (+12 - +26) and platelet rose to 50 x 109 /L on day +27 (+19 -+35) respectively. The blood products support, the antibiotics used, and total environment protection duration decreased. Acute GVHD presented in 7 patients (50.0%). Four patients died in acute GVHD and infection on days of +73, +41 +57 and +49. The disease free survival days after AIIo-PBSCT in the 10 patients was +137 (+91 - +240) days. It is suggested that AIIo-PBSCT probably has some advantage than that of AIIo-BMT.},
issn = {1993-0631}, url = {https://cjcr.amegroups.org/article/view/2028}
}